Podcast Sponsor: Biotix, Inc. - Free Samples
Guest:
Martin LeBlanc, CEO, Caprion, Bio and Contact Info
Listen (1:07) Proteomics overshadowed by DNA sequencing?
Listen (7:17) Caprion and CellCarta
Listen (4:34) Novel drug targets and biomarker candidates
Listen (3:10) Promise of proteomics and protein diagnostics
Listen (7:11) Proteomics and genomics
Listen (2:57) A Human Proteome Project?
Listen (4:49) Proteomics outlook
As part of a series on Personalized Medicine, today we explore a leading company in the field of protein biomarker discovery, Caprion Proteomics. Caprion’s proprietary technology, CellCarta, enables comprehensive measurement of protein expression differences across large sets of biological samples. They have been providing protein biomarker and target identification services to over 30 major pharma industry clients in all of the major disease areas. Here to talk to us about the field of proteomics and his company is the CEO of Caprion, Martin Leblanc.
